Skip to main content
. 2019 Dec 6;9:18533. doi: 10.1038/s41598-019-55149-z

Table 1.

Patient demographics.

Characteristics Daptomycin susceptibility P-value
Sensitive (%) Resistant (%)
Total 1299 (97.2) 38 (2.8)
Age
<65 632 (48.7) 18 (47.4) 0.876
≥65 667 (51.4) 20 (52.6)
Sex (male/female)
Male 772 (59.4) 24 (63.2) 0.645
Female 527 (40.6) 14 (36.8)
Implantation, catheter
With 223 (17.2) 11 (28.9) 0.060
Without 1076 (82.8) 27 (71.1)
Previous glycopeptide use
Yes 305 (23.5) 17 (44.7) 0.003
No 994 (76.5) 21 (55.3)
Vancomycin susceptibility
MIC < 2 mg/L 1016 (78.2) 27 (71.1) 0.293
MIC ≥ 2 mg/L 283 (21.8) 11 (28.9)
Teicoplanin susceptibility
MIC < 16 mg/L 1212 (93.3) 23 (60.5) <0.0001*
MIC ≥ 16 mg/L 87 (6.7) 15 (39.5)
Previous linezolid use
Yes 29 (2.2) 2 (5.3) 0.219
No 1270 (97.8) 36 (94.7)
Previous daptomycin use
Yes 91 (7.0) 7 (18.4) 0.018*
No 1208 (93.0) 31 (81.6)
Previous penicillin use
Yes 469 (36.1) 21 (55.3) 0.016
No 830 (63.9) 17 (44.7)
Previous cephem use
Yes 863 (66.4) 28 (73.7) 0.350
No 436 (33.6) 10 (26.3)
Previous carbapenem use
Yes 497 (38.3) 22 (57.9) 0.014
No 802 (61.7) 16 (42.1)
Previous aminoglycoside use
Yes 97 (7.5) 3 (7.9) 0.921
No 1202 (92.5) 35 (92.1)
Previous tetracycline use
Yes 68 (5.2) 6 (15.8) 0.016*
No 1231 (94.8) 32 (84.2)
Previous fluoroquinolone use
Yes 659 (50.7) 24 (36.8) 0.131
No 640 (49.3) 14 (63.2)
Previous sulfamethoxazole/trimethoprim use
Yes 237 (18.2) 7 (18.4) 0.978
No 1062 (81.8) 31 (81.6)

*The Fisher’s exact test.